The  ||| S:0 E:4 ||| DT
oxidative  ||| S:4 E:14 ||| JJ
stress  ||| S:14 E:21 ||| NN
in  ||| S:21 E:24 ||| IN
pathogenesis  ||| S:24 E:37 ||| NN
of  ||| S:37 E:40 ||| IN
arterial  ||| S:40 E:49 ||| JJ
hypertension  ||| S:49 E:62 ||| NN
-  ||| S:62 E:64 ||| :
role  ||| S:64 E:69 ||| NN
of  ||| S:69 E:72 ||| IN
methylated  ||| S:72 E:83 ||| JJ
arginines  ||| S:83 E:93 ||| JJ
Oxidative  ||| S:93 E:103 ||| JJ
stress  ||| S:103 E:110 ||| NN
plays  ||| S:110 E:116 ||| VBZ
significant  ||| S:116 E:128 ||| JJ
role  ||| S:128 E:133 ||| NN
in  ||| S:133 E:136 ||| IN
pathogenesis  ||| S:136 E:149 ||| NN
of  ||| S:149 E:152 ||| IN
cardiovascular  ||| S:152 E:167 ||| JJ
diseases ||| S:167 E:175 ||| NNS
.  ||| S:175 E:177 ||| .
Imbalance  ||| S:177 E:187 ||| NN
of  ||| S:187 E:190 ||| IN
antioxidants  ||| S:190 E:203 ||| NN
and  ||| S:203 E:207 ||| CC
reactive  ||| S:207 E:216 ||| JJ
oxygen  ||| S:216 E:223 ||| NN
species  ||| S:223 E:231 ||| NN
contributes  ||| S:231 E:243 ||| VBZ
to  ||| S:243 E:246 ||| TO
endothelium  ||| S:246 E:258 ||| VB
damage  ||| S:258 E:265 ||| NN
and  ||| S:265 E:269 ||| CC
leads  ||| S:269 E:275 ||| VBZ
to  ||| S:275 E:278 ||| TO
hypertension ||| S:278 E:290 ||| VB
.  ||| S:290 E:292 ||| .
The  ||| S:292 E:296 ||| DT
knowledge  ||| S:296 E:306 ||| NN
on  ||| S:306 E:309 ||| IN
these  ||| S:309 E:315 ||| DT
processes  ||| S:315 E:325 ||| NNS
may  ||| S:325 E:329 ||| MD
contribute  ||| S:329 E:340 ||| VB
to  ||| S:340 E:343 ||| TO
prevention  ||| S:343 E:354 ||| NN
and  ||| S:354 E:358 ||| CC
therapy  ||| S:358 E:366 ||| NN
of  ||| S:366 E:369 ||| IN
cardiovascular  ||| S:369 E:384 ||| JJ
diseases ||| S:384 E:392 ||| NNS
.  ||| S:392 E:394 ||| .
This  ||| S:394 E:399 ||| DT
paper  ||| S:399 E:405 ||| NN
describes  ||| S:405 E:415 ||| VBZ
the  ||| S:415 E:419 ||| DT
role  ||| S:419 E:424 ||| NN
of  ||| S:424 E:427 ||| IN
methylated  ||| S:427 E:438 ||| JJ
arginines  ||| S:438 E:448 ||| NN
in  ||| S:448 E:451 ||| IN
pathogenesis  ||| S:451 E:464 ||| NN
of  ||| S:464 E:467 ||| IN
arterial  ||| S:467 E:476 ||| JJ
hypertension ||| S:476 E:488 ||| NN
,  ||| S:488 E:490 ||| ,
which  ||| S:490 E:496 ||| WDT
are  ||| S:496 E:500 ||| VBP
nowadays  ||| S:500 E:509 ||| RB
object  ||| S:509 E:516 ||| VB
of  ||| S:516 E:519 ||| IN
wide  ||| S:519 E:524 ||| JJ
research  ||| S:524 E:533 ||| NN
and  ||| S:533 E:537 ||| CC
pathways  ||| S:537 E:546 ||| VB
involved  ||| S:546 E:555 ||| VBN
in  ||| S:555 E:558 ||| IN
their  ||| S:558 E:564 ||| PRP$
formation  ||| S:564 E:574 ||| NN
and  ||| S:574 E:578 ||| CC
metabolism  ||| S:578 E:589 ||| NNS
are  ||| S:589 E:593 ||| VBP
often  ||| S:593 E:599 ||| RB
recognised  ||| S:599 E:610 ||| VBN
as  ||| S:610 E:613 ||| IN
potential  ||| S:613 E:623 ||| JJ
targets  ||| S:623 E:631 ||| NNS
for  ||| S:631 E:635 ||| IN
cardiovascular  ||| S:635 E:650 ||| JJ
drugs ||| S:650 E:655 ||| NNS
.  ||| S:655 E:657 ||| .
